Anaroxyl 5 mg Injection should be administered slowly over at least 15 seconds intramuscularly (deep into the gluteal muscle) or intravenously (over 1 minute into a vein).

Anaroxyl inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins, which are key mediators of pain, inflammation, and fever.

• •Hypersensitivity to Anaroxyl or other NSAIDs
• •Active gastrointestinal bleeding or peptic ulcer
• •Severe renal or hepatic impairment
• •Severe heart failure
• •Third trimester of pregnancy
• •Patients undergoing coronary artery bypass graft (CABG) surgery

Store below 30°C in a dry place, away from light. Do not freeze.

Symptoms may include nausea, vomiting, abdominal pain, lethargy, dizziness, tinnitus. Severe overdose can lead to acute renal failure, hepatic dysfunction, respiratory depression, and coma. Treatment is symptomatic and supportive; there is no specific antidote.

Avoid during the third trimester of pregnancy due to potential fetal harm (premature closure of ductus arteriosus). Use with caution in earlier trimesters only if potential benefit outweighs risk. Not recommended during breastfeeding as it may be excreted in breast milk.